Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 101 to 110 of 426 total matches.

Drugs for Chronic Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
of falls. The Medical Letter ® Vol. 65 (1667) January 9, 2023 2 Benzodiazepine receptor agonists ...
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. CBT-I includes stimulus control, sleep education and hygiene, sleep restriction, relaxation training, and cognitive therapy. When CBT-I alone is not effective, pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6   doi:10.58347/tml.2023.1667a |  Show IntroductionHide Introduction

Treatment of Common Respiratory Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
The Medical Letter ® Vol. 65 (1674) April 17, 2023 58 Table 1. Empiric Treatment of Some Outpatient ...
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62   doi:10.58347/tml.2023.1674a |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
creatinine clearance, have been reported with long-term use of The Medical Letter ® Vol. 66 (1699) April 1 ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
by methotrexate. The Medical Letter ® Vol. 63 (1637) November 15, 2021 Table 1. Some Conventional DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
completion of therapy. The Medical Letter ® Vol. 64 (1647) April 4, 2022 50 recommended. PPIs decrease ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
Letter ® Vol. 65 (1684) September 4, 2023 138 Table 1. Drugs for Maintenance Treatment of Opioid Use ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
involving the face and intertriginous areas. The Medical Letter ® Vol. 66 (1712) September 30, 2024 154 ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
to achieve weight loss of The Medical Letter ® Vol. 67 (1734) August 4, 2025 at least 10% (81.6% vs 60.5 ...
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8   doi:10.58347/tml.2025.1734a |  Show IntroductionHide Introduction

Seasonal Influenza Vaccination: 2026-2027

   
The Medical Letter on Drugs and Therapeutics • Oct 12, 2026  (Issue 1765)
consistent direction while the federal advisory process remains paused. The Medical Letter ® Vol. 68 (1765 ...
Annual influenza vaccination is recommended for all persons ≥6 months old without a contraindication. Influenza vaccines available this season in the US are listed in Table 3.
Med Lett Drugs Ther. 2026 Oct 12;68(1765):161-7   doi:10.58347/tml.2026.1765a |  Show IntroductionHide Introduction

In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
/policies/drug-pricing-policy. The Medical Letter ® Vol. 65 (1668) January 23, 2023 torsemide bumetanide ...
The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):14-5   doi:10.58347/tml.2023.1668d |  Show IntroductionHide Introduction